Forget the slow moving BHP Billiton Limited (ASX: BHP) or Wesfarmers Ltd (ASX: WES), there are a number of ASX stocks which have already performed exceptionally well for shareholders, but appear primed for further outperformance in the future. For example, all three of the stocks below have crushed the S&P/ASX 200 Index’s (ASX: XJO) (INDEX: ^AXJO) 12-month return of just 11.48%.
The first stock that’s firmly on my long-term buy list is FSA Group Limited (ASX: FSA). FSA helps individuals with debt problems and businesses with cash flow management. Whilst its business model might sound boring, it’s a silent achiever which has gained 84% in the past 12 months. However with a juicy fully franked dividend, rapidly growing profits and cheap share price, I think there’s more to come (it’s the reason I made it my top stock pick for July).
The second stock which I believe has a bright future ahead is Vita Life Sciences (ASX: VSC). It is an $87 million company involved in the manufacture and distribution of vitamins and supplements throughout Australia and Asia. In the past five years sales have grown at an average rate of 16.1%. In 2014 management have set guidance of between 13% and 15% revenue growth and an EBIT margin of 15%. Whilst Australia remains a competitive market, Asia now accounts for 60% of group revenue.
Liquefied Natural Gas Limited (ASX: LNG) has proven to be the ASX’s hottest stock of 2014, increasing some 645% so far. Although it is yet to make a profit, LNGL is moving towards the development of an eight million tonnes per annum (8mtpa) LNG liquefaction and export facility in Lake Charles, Louisiana USA. If the company can get the necessary funding and approvals for the Magnolia project, it could generate EBITDA of up $750 million per annum by 2021. Although there is a considerable risk that nothing may eventuate from the project, some of the world’s biggest and best fund managers have taken up substantial holdings in the company with the expectation it’ll be successful. If everything goes according to plan, its current market price of $2.20 per share could prove to be cheap.
ADMEDUS FPO (ASX: AHZ) is a junior biotechnology stock with considerable upside potential. Admedus is involved in the development, manufacture and distribution of a tissue regeneration technology known as Cardiocel. With six years passed since clinical trials, Admedus has received US and European approval to market the technology which allows it to increase revenues significantly in coming years. In addition the company continues with its vaccines program and distribution of medical devices. At $0.13 per share I think it is a somewhat risky, but good long-term buy and hold.
Our BEST dividend stock idea – FREE!
Each of these companies hold significant long-term potential from their current prices. However they are risky and only one (FSA) pays an attractive dividend. Fast growing companies which can pay a BIG dividend usually don’t remain hidden from the market for long.
This Tiny ASX Stock Could Be the Next Afterpay
One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting...
Because 'Doc' Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget 'buy now pay later', this stock could be the next hot stock on the ASX.
Doc and his team have published a detailed report on this tiny ASX stock. Find out how you can access what could be the NEXT Afterpay today!
Returns as of 6th October 2020
Motley Fool Contributor Owen Raszkiewicz owns shares in Admedus FPO and Liquefied Natural Gas Limited.
- ALL ORDINARIES finishes higher Monday: 10 shares you missed – October 30, 2017 4:44pm
- Are these the secrets behind Australia’s best ASX investors? – October 30, 2017 3:43pm
- My Aussie Share Market Investing Do’s of 2017/2018 – October 30, 2017 1:13pm